| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
208.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $22.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-08-19 |
4 |
AS |
$38.72 |
$168,175 |
D/D |
(4,300) |
293,614 |
|
-7% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-07-22 |
4 |
AS |
$42.22 |
$238,025 |
D/D |
(5,626) |
297,914 |
|
20% |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2020-06-23 |
4 |
AS |
$70.00 |
$1,881,250 |
D/D |
(26,875) |
45,875 |
|
-42% |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2020-06-23 |
4 |
OE |
$35.40 |
$1,051,344 |
D/D |
26,875 |
72,750 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-06-17 |
4 |
AS |
$65.56 |
$495,366 |
D/D |
(7,501) |
303,540 |
|
-41% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-05-20 |
4 |
AS |
$59.88 |
$449,580 |
D/D |
(7,501) |
311,041 |
|
-38% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-04-24 |
4 |
AS |
$60.00 |
$135,000 |
D/D |
(2,250) |
57,018 |
|
-31% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-04-24 |
4 |
OE |
$26.41 |
$59,423 |
D/D |
2,250 |
59,268 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-04-22 |
4 |
AS |
$56.80 |
$533,205 |
D/D |
(9,376) |
318,542 |
|
-28% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-04-22 |
4 |
OE |
$7.53 |
$70,601 |
D/D |
9,376 |
327,918 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-03-18 |
4 |
AS |
$40.57 |
$233,352 |
D/D |
(5,626) |
318,542 |
|
-8% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-03-18 |
4 |
OE |
$7.53 |
$42,364 |
D/D |
5,626 |
324,168 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-03-04 |
4 |
AS |
$52.00 |
$823,500 |
D/D |
(15,750) |
57,018 |
|
-19% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-03-04 |
4 |
OE |
$26.41 |
$415,958 |
D/D |
15,750 |
72,768 |
|
- |
|
| Meek David D. |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
4,571 |
|
- |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,380 |
59,090 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
33,789 |
318,542 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
16,191 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
8,068 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
4,486 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,253 |
57,018 |
|
- |
|
| Van Deventer Sander |
EVP, Research & Product Dev. |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,380 |
61,599 |
|
- |
|
| Schaffer David |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
46,978 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
8,068 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
8,068 |
|
- |
|
336 Records found
|
|
Page 8 of 14 |
|
|
0.01 (0.21%) 
